title: [The influence of genetic factors on the effectiveness of eradication therapy of Helicobacter pylori infection in children].
abstract: Efficacy of sequential eradication therapy for H. pylori was studied in 176 adolescents (mean age 14.3 years) with different PPI metabolism types. Group I consisted from the patients received omeprazole as PPI in combined treatment with amoxycilline, clarithromycine and tinidazole, Group II--patients treated with rabeprazole in the combination with the same antibacterial drugs. In all the patients, CYP2C19 genotype was identified as a control rate of PPI metabolism (extensive, intermediate and poor metabolizers). Sequential therapy in the children with intermediate and poor metabolic activity demonstrated a high eradication rate irrespective of PPI type (> 80%). In the patients with extensive metabolism taking omeprazole, eradication standard turned out to be lower (63.4%) than in the rabeprazole group (82.3%) (p = 0.026). Results of our survey confirmed a potential advantage of rabeprazole-based treatment compared with omeprazole-containing regimen in the sequential treatment of H. pylori infection in childhood.
authors: A A
authors: AA
authors: Nizhevich
authors: È N
authors: ÈN
authors: Akhmadeeva
authors: V U
authors: VU
authors: Sataev
authors: F S
authors: FS
authors: Bilalov
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000378:metabolism; D065731:Cytochrome P-450 CYP2C19; D005260:Female; D005838:Genotype; D016481:Helicobacter Infections / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D016480:Helicobacter pylori; D006801:Humans; D008297:Male
chemical_list: D000900:Anti-Bacterial Agents; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19